New Executive Leadership at Acupath Labs

PLAINVIEW, N.Y., Jan. 18, 2017 /PRNewswire/ -- Acupath Laboratories, Inc., a leading provider of sub-specialized anatomic pathology services, announces the formation of an Executive Committee that will guide the company's vision and strategy in 2017 and beyond.

John Cucci, a 15-year veteran of the anatomic pathology industry, has been promoted from Director of Business Development to Chief Sales Officer.  Prior to joining Acupath Labs in 2015, Mr. Cucci served in senior sales leadership roles at several leading lab industry organizations including, P4 Diagnostix (formerly Theranostix), VitalAxis, PLUS Diagnostics, and Dianon Pathology (LabCorp).  Mr. Cucci will be responsible for developing and executing the company's strategy as it pertains to new markets, tests, and services.

Steve Kamalic, a 30-year veteran of the lab industry, assumes the role of Chief Operating Officer, having worked previously as Director of Sales at Acupath since 2013, during which time he led the company to 30% specimen volume growth.  Mr. Kamalic has extensive experience in all aspects of the lab business and will oversee the company's day to day operations.   

Zaleena Neice, who joined Acupath in 2008 as the Controller, has been elevated to the position of Chief Financial Officer.  Mrs. Neice has played an instrumental role in helping the company achieve significant success during her tenure, ensuring that the company has a strong financial foundation for the long term. 

"2017 represents a new beginning for Acupath.  We are proud of the exceptional service levels that we offer, especially as it relates to our industry best turnaround time (24-48 hours for most tests) and our immediate, one-on-one client communication.  It is our goal to leverage our extensive in-network insurance coverage to build on the success of the past and create a bigger, better Acupath that is focused on helping our physician, hospital, and lab partners deliver the best possible patient care, while operating most efficiently and profitably.  Finally, the Q1 launch of our hematology oncology division, Cancer Diagnostics Institute (CDI), will open up an exciting new market where we can leverage our new 10 color BD FACSCanto™ flow cytometry system to deliver best-in-class diagnostic services," the Executive Committee said in a statement.

About Acupath Laboratories, Inc.

Founded in 1998 and based in Plainview, NY (Long Island), Acupath is a provider of sub-specialized anatomic pathology services focused on the following specialties; Urology, Gastroenterology, Dermatology, Women's Health, Otolaryngology, Podiatry, and Hematology / Oncology.  Acupath offers an extensive test menu on both a global and TC/PC basis, processes well over 150,000 specimens annually, and is one of the leading providers of cutting edge FISH testing for the detection of bladder cancer (UroVysion™), prostate cancer (PTEN ERG), and esophageal cancer (Barrett's esophagus FISH).

Contact:

Denise Corpion
Media Relations
516-394-5580
dcorpion@acupath.com

This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-executive-leadership-at-acupath-labs-300392949.html

SOURCE Acupath Laboratories, Inc.